14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price

5. Johnson & Johnson (NYSE:JNJ)

Number of Hedge Fund Holders In Q1 2025: 91

Johnson & Johnson (NYSE:JNJ) is one of the largest and most well-known pharmaceutical companies in the world. Its shares have gained a modest 8.9% year-to-date as the firm has struggled from headwinds such as a judge rejecting its $10 billion talc powder cancer lawsuit settlement. In his previous comments about Johnson & Johnson (NYSE:JNJ), Cramer has called the firm one of the “best-run companies in America” and praised its balance sheet and drug pipeline. This time around, he discussed the upcoming earnings report and an analyst note:

“[On a Mizuho note saying POTUS would praise LLY and JNJ] I would love that, that won’t happen. You know why it won’t happen? See there’s someone in the health and human services department that’s not crazy about, about big pharma and the way we think about it.

“JNJ, JNJ I don’t know. JNJ’s going to report this week they’ve got a talc problem still but I thought the President was going to act against the plaintiffs, probably has.”

As for Johnson & Johnson (NYSE:JNJ) ‘s balance sheet and pipeline, here’s what Cramer said:

“Or let’s consider Johnson & Johnson, triple A balance sheet, many drugs in the pipeline, one of the best-run companies in America, if not the world, with perhaps the most billion-dollar franchises of any pharmaceutical company I know, but JNJ only yields 3.55%, and it’s got this terrible legal overhang related to allegations that its talcum powder, no longer in the market, caused ovarian cancer. We don’t know how open-ended the claims are. Can you tolerate that risk? I’d love to say just go buy JNJ, but where? What price? That yield is no longer enough to compensate you for the risk, especially if you don’t know if RFK Jr dislikes some of their drug delivery mechanisms and formulas, so people are staying away from that, too, not just because of the bonds. JNJ… 3.3%.”